Pharmaceutical composition containing decoy and use of the same

Abstract

A pharmaceutical composition is provided for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.

What is claimed is:  
     
         1 . A pharmaceutical composition for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-κB or ets, the composition comprising: 
 at least one decoy; and  
 a pharmaceutically acceptable carrier.  
 
     
     
         2 . A composition according to  claim 1 , wherein the at least one decoy is an NF-κB decoy or a derivative, variant or fragment thereof, and the derivative, variant or fragment thereof has biological activity.  
     
     
         3 . A composition according to  claim 1 , wherein the at least one decoy is an NF-κB decoy.  
     
     
         4 . A composition according to  claim 1 , wherein the at least one decoy is an ets decoy.  
     
     
         5 . A composition according to  claim 1 , wherein the at least one decoy is a chimera decoy of NF-κB and ets.  
     
     
         6 . A composition according to  claim 1 , wherein the disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture.  
     
     
         7 . A composition according to  claim 1 , wherein the pharmaceutically acceptable carrier is a hydrophilic polymer.  
     
     
         8 . A composition according to  claim 1 , wherein the pharmaceutically acceptable carrier is a liposome.  
     
     
         9 . A pharmaceutical composition for treatment and/or prevention of a disease, a disorder and/or a condition caused by eosinophilic abnormality, the composition comprising: 
 at least one decoy; and    a pharmaceutically acceptable carrier.    
     
     
         10 . A composition according to  claim 9 , wherein the at least one decoy is an NF-κB decoy or a derivative, variant or fragment thereof, and the derivative, variant or fragment thereof has biological activity.  
     
     
         11 . A composition according to  claim 9 , wherein the at least one decoy is an NF-κB decoy.  
     
     
         12 . A composition according to  claim 9 , wherein the at least one decoy is an ets decoy.  
     
     
         13 . A composition according to  claim 9 , wherein the at least one decoy are an NF-κB decoy and an ets chimera decoy.  
     
     
         14 . A composition according to  claim 9 , wherein the disease is selected from the group consisting of asthma, allergic diseases, skin diseases, and mycosis.  
     
     
         15 . A composition according to  claim 9 , wherein the disease is selected from the group consisting of bronchial asthma, childhood asthma, allergic asthma, atopic asthma, steroid-resistant asthma (SRA), non-allergic asthma, intrinsic asthma, extrinsic asthma, aspirin-induced asthma, cardiac asthma, and infectious asthma.  
     
     
         16 . A composition according to  claim 9 , wherein the pharmaceutically acceptable carrier is a hydrophilic polymer.  
     
     
         17 . A composition according to  claim 9 , wherein the pharmaceutically acceptable carrier is a liposome.